Assessing bioequivalence of generic modified-release antiepileptic drugs.
about
AES Position Statement on Generic Substitution of Antiepileptic Drugs.Generic Modified-Release Antiepileptic Drugs: No Difference Within Formulations, but Important Differences Across FormulationsIncreased receptor activity-modifying protein 1 in the nervous system is sufficient to protect against autonomic dysregulation and hypertension.Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
P2860
Assessing bioequivalence of generic modified-release antiepileptic drugs.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Assessing bioequivalence of generic modified-release antiepileptic drugs.
@en
Assessing bioequivalence of generic modified-release antiepileptic drugs.
@nl
type
label
Assessing bioequivalence of generic modified-release antiepileptic drugs.
@en
Assessing bioequivalence of generic modified-release antiepileptic drugs.
@nl
prefLabel
Assessing bioequivalence of generic modified-release antiepileptic drugs.
@en
Assessing bioequivalence of generic modified-release antiepileptic drugs.
@nl
P2093
P2860
P1433
P1476
Assessing bioequivalence of generic modified-release antiepileptic drugs
@en
P2093
Barbara Davit
Barry E Gidal
Gregory L Krauss
Yi-Ting Chang
P2860
P304
P356
10.1212/WNL.0000000000002607
P407
P577
2016-03-25T00:00:00Z